These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 30091945

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
    Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, Shulkin B, Qumseya A, Routh JC, MacDonald T, Feinberg S, Crompton B, Rudzinski ER, Arnold M, Venkatramani R.
    Lancet Oncol; 2024 Jul; 25(7):912-921. PubMed ID: 38936378
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CA.
    J Clin Oncol; 2016 Jan 10; 34(2):117-22. PubMed ID: 26503200
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB, Vietti T, Gehan E, Wiener E, Wharam M, Newton WA, Maurer H.
    J Pediatr Hematol Oncol; 1995 Nov 10; 17(4):331-7. PubMed ID: 7583389
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol.
    Miyachi M, Tsuchiya K, Hosono A, Ogawa A, Koh K, Kikuta A, Hara J, Teramukai S, Hosoi H.
    Medicine (Baltimore); 2019 Dec 10; 98(52):e18344. PubMed ID: 31876708
    [Abstract] [Full Text] [Related]

  • 10. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS.
    Cancer; 2017 Jun 15; 123(12):2368-2375. PubMed ID: 28211936
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH, Children's Oncology Group.
    J Clin Oncol; 2007 Feb 01; 25(4):362-9. PubMed ID: 17264331
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, Anderson JR, Crist WM, Link MP.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [Abstract] [Full Text] [Related]

  • 16. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL, Lyden ER, Arndt CA, Hawkins DS, Anderson JR, Rodeberg DA, Morris CD, Donaldson SS.
    Int J Radiat Oncol Biol Phys; 2015 Dec 01; 93(5):1071-6. PubMed ID: 26581144
    [Abstract] [Full Text] [Related]

  • 17. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3844-51. PubMed ID: 16921036
    [Abstract] [Full Text] [Related]

  • 18. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
    Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W.
    J Clin Oncol; 2004 May 15; 22(10):1894-901. PubMed ID: 15143082
    [Abstract] [Full Text] [Related]

  • 19. The VAC regimen for adult rhabdomyosarcoma: Differences between adolescent/young adult and older patients.
    Nakano K, Ae K, Matsumoto S, Takahashi S.
    Asia Pac J Clin Oncol; 2020 Apr 15; 16(2):e47-e52. PubMed ID: 31657883
    [Abstract] [Full Text] [Related]

  • 20. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.
    Russell HV, Chi YY, Okcu MF, Bernhardt MB, Rodriguez-Galindo C, Gupta AA, Hawkins DS.
    Cancer; 2022 Jan 15; 128(2):317-325. PubMed ID: 34623638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.